Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Gains from Investment Securities (2016 - 2025)

Palisade Bio (PALI) has disclosed Gains from Investment Securities for 14 consecutive years, with $89400.0 as the latest value for Q1 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $89400.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $355000.0, a 1.76% increase, with the full-year FY2024 number at $12300.0, down 98.16% from a year prior.
  • Gains from Investment Securities was $89400.0 for Q1 2025 at Palisade Bio, up from $12300.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.5 million in Q1 2022 to a low of $2967.0 in Q1 2023.
  • A 5-year average of $452836.9 and a median of $125939.5 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 234.31% in 2023; the steepest drop was 99.88% in 2023.
  • Palisade Bio's Gains from Investment Securities stood at $87025.0 in 2021, then soared by 307.93% to $355000.0 in 2022, then surged by 53.01% to $543188.0 in 2023, then tumbled by 97.74% to $12300.0 in 2024, then soared by 626.83% to $89400.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Gains from Investment Securities are $89400.0 (Q1 2025), $12300.0 (Q4 2024), and $543188.0 (Q3 2023).